Our involvement began with the early stage commercial launch of the product and continues through to the eventual development of global mass production and manufacturing facilities capable of producing up to 120 million devices per year.
Phase 1 included delivery of both new build and refurbished manufacturing laboratory space, new assembly and packing lines, blending suites and dry powder filling lines, laboratory equipment, new third party plastics sub-assembly and moulding capability together with warehouse space.
Following on from this initial phase, G&T was appointed to provide services for a £56m three-storey manufacturing facility for the inhaler system including a new 4,500m² extension capable of accommodating an assembly and packing line alongside a dedicated laboratory.
Phase 3 involved the conversion of an onsite catering facility into a second manufacturing facility in the US together with the refurbishment of laboratory space and filling suites.
Phases 4 and 5 saw the conversion of a production facility together with installation of new equipment and the delivery of further manufacturing capacity increase at sites across the GSK Global Network.